This trial is looking at whether electronic provider notification of severe aortic stenosis impacts its management, on the utilization of aortic valve replacement, and on ethnic and racial disparities in AVR utilization.
1 Primary · 4 Secondary · Reporting Duration: 1 year
Active Control
Experimental Treatment
940 Total Participants · 2 Treatment Groups
Primary Treatment: Physician Notification Letter · No Placebo Group · N/A
Age 18+ · All Participants · 1 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: